薬物制御されたCAR T細胞は,細胞の相互作用を調節することによって細胞を制御します
Leo Scheller1,2, Greta Maria Paola Giordano Attianese3, Rocío Castellanos-Rueda4,5
1Laboratory of Protein Design and Immunoengineering, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.
Nature chemical biology
|February 19, 2026
まとめ
新しい薬物調節オフスイッチCAR T細胞療法 (DROP-CARs) は,小分子でT細胞活動を制御することで,現在のCAR T細胞治療の限界に対処し,安全性と有効性を高めます.
科学分野:
- 免疫療法による免疫療法です.
- 合成生物学 合成生物学とは
- 分子工学は分子工学である.
背景:
- 化学抗原受容体 (CAR) T細胞療法では,長期の抗原被曝により,標的内および腫瘍外の毒性およびT細胞枯渇などの課題に直面しています.
- 小分子スイッチを備えた既存のCAR設計は,安全で臨床的に承認された薬剤に反応する適切な非免疫原性タンパク質成分の可用性によって制限されています.
研究 の 目的:
- 新薬規制のCAR T細胞システム (DROP-CARs) を開発し,安全性と治療制御を向上させる.
- 小さな分子を活用してT細胞活動と腫瘍標的を調節するCARを設計する.
主な方法:
- 人体タンパク質-タンパク質相互作用 (PPI) の合理的な設計とライブラリベースの最適化により,venetoclax制御の"薬物規制オフスイッチPPI" (DROP) -CARs.
- STAT3シグナル伝達のための異なる小分子と論理ゲートされた合成受容体に対応する二重DROP-CARの開発.
- エンジニアリングされたCAR T細胞のインビトロおよびインビボ機能評価.
主要な成果:
- DROP-CARsは,腫瘍を標的とするscFvの投与量依存の放出を可能にし,T細胞と腫瘍細胞の結合を減少させます.
- デュアルDROP-CARとロジックゲート合成受容体の概念実証が成功しました.
- エンジニアリングされたDROP-CAR T細胞は,in vitroおよびin vivoで機能的活性を示した.
結論:
- DROP-CAR技術は,CAR T細胞療法の安全性と有効性を高めるための有望な戦略を提供します.
- このアプローチは,臨床的に承認された小分子を用いて,T細胞活動の正確な制御を可能にします.
- 開発されたシステムは,がん免疫療法における将来の臨床応用の可能性を秘めています.
関連する概念動画
01:22T Cell Activation and Clonal Selection
13.7K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
13.7K
01:24T Cell Types and Functions
3.2K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.2K
01:27Cytotoxic T Cells-mediated Immune Response
7.1K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
7.1K
01:27Tumor Immunotherapy
2.6K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.6K